Bezlotoxumab denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for bezlotoxumab are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Bezlotoxumab for Quantity Limits

Aetna's quantity-limit denial for bezlotoxumab reflects the plan's coverage policy restricting reimbursement to a defined quantity or number of administrations within a specified period. Bezlotoxumab is typically administered as a single intravenous infusion, so a quantity-limit denial in this context usually means either that a second infusion is being requested following a new episode of infection, or that the plan has restricted coverage to a lifetime limit and the patient has reached it. The clinical question is whether the current or requested administration falls within the medically necessary use as defined by the FDA label and Aetna's own policy.

## Why This Denial Is Appealable

If the patient has experienced a new, distinct C. difficile recurrence — rather than a continuation of the same treated episode — the clinical and biological circumstances for a subsequent infusion may differ meaningfully from the first. A prescriber who can document that this is a new recurrent episode, with its own laboratory confirmation and clinical context, has a reasonable basis to argue that the quantity limit should not bar coverage for a genuinely new medically necessary event.

## Federal Appeal Framework

• Internal appeal (ERISA §503 / ACA): File within the deadline in the denial notice. Request Aetna's quantity-limit policy for bezlotoxumab as part of your preparation.
• External review (ACA §2719): If the internal appeal is denied, an IRO reviews whether the quantity limit is consistent with generally accepted medical standards. Window is approximately four months from final internal denial.
• Expedited track: Available with prescriber certification of urgent need.

## Concrete Appeal Steps

1. Request Aetna's current quantity-limit criteria for bezlotoxumab and the specific limit that was exceeded. 2. Obtain the FDA-approved prescribing label (Zinplava) and review the indication language regarding repeat use. 3. Have your prescriber document the current episode as a distinct event — new laboratory confirmation, new clinical presentation, and medical rationale for re-treatment. 4. Submit the appeal with a prescriber letter and all supporting records.

## Documentation to Gather

• Current-episode diagnosis: New laboratory confirmation of C. difficile with date, distinguishing this from the prior treated episode.
• Prior-episode records: Documentation of the previous infusion, its date, and the patient's subsequent clinical course.
• Prescriber medical-necessity letter: Explaining the basis for re-treatment, addressing the FDA label's indication language, and arguing that the new episode constitutes a separate medically necessary event.
• Clinical course notes: Chart notes documenting the interval between episodes, any treatment in between, and the clinical circumstances at the time of the new request.

## Criteria-Mapping Structure

Pull Aetna's quantity-limit policy and identify (a) the stated limit and (b) any exception criteria. Map each exception criterion to the chart: new diagnosis date, new lab result, clinical differentiation from prior episode, and prescriber attestation. If the FDA label addresses repeat administration, quote the relevant language directly. The goal is to show that this administration is not excess use within a single treatment episode but a clinically distinct event warranting separate coverage consideration.